IL13RA2 and cancer: Immunotherapeutic strategies other than checkpoint blockade are also being evaluated in pHGGs, including cancer peptide vaccine therapy with antigens such as Ephrin A2 (EphA2), interleukin 13 receptor alpha 2 (IL13Ra2), survivin and HLA-A2 (NCT01130077) [126,127,128], autologous dendritic cell vaccine therapy [129], and chimeric antigen receptor (CAR)-T therapy where studies are recruiting (anti-IL13aR2; NCT02208362, anti-GD2; NCT04196413, anti-B7 H3; NCT04185038).